*These authors contributed equally to this work.
Article first published online: 14 OCT 2012
Copyright © 2012 American Association for the Study of Liver Diseases
Volume 56, Issue 5, pages 1661–1670, November 2012
How to Cite
Zhao, Q., Peng, L., Huang, W., Li, Q., Pei, Y., Yuan, P., Zheng, L., Zhang, Y., Deng, J., Zhong, C., Hu, B., Ding, H., Fang, W., Li, R., Liao, Q., Lin, C., Deng, W., Yan, H., Hou, J., Wu, Q., Xu, T., Liu, J., Hu, L., Peng, T., Chen, S., Lai, K. N., Yuen, M.-F., Wang, Y., Maini, M. K., Li, C., Li, M., Wang, J., Zhang, X., Sham, P.-C., Wang, J., Gao, Z.-L. and Wang, Y. (2012), Rare inborn errors associated with chronic hepatitis B virus infection. Hepatology, 56: 1661–1670. doi: 10.1002/hep.25850
Potential conflict of interest: nothing to report
Supported by the State 985 project and National Science and Technology Major Project (2012 ZX10002007) of China, the Fundamental Research Funds for the Central Universities (10ykjc07), China Medical Board in New York (050827), and Guangdong Provincial Science and Technology Foundation (10151008901000003).
Database repository: NCBI accession number: SRA048741. Accession numbers: GenBank RefSeq: TMEM2 NM_013390, IFNA2 NM_000605, NLRX1 NM_170722, C2 NM_000063, IL1R2 NM_004633, ERAP1 NM_016442.
- Issue published online: 31 OCT 2012
- Article first published online: 14 OCT 2012
- Accepted manuscript online: 18 MAY 2012 11:49AM EST
- Manuscript Accepted: 7 MAY 2012
- Manuscript Received: 3 JAN 2012
Chronic hepatitis B (CHB) is a major global health issue. The role of rare genetic variants in CHB has not been elucidated. We aimed to identify rare allelic variants predisposing to CHB. We performed exome sequencing in 50 CHB patients who had no identifiable risk factors for CHB and 40 controls who were healthy and hepatitis B surface antibody-positive, but had never received hepatitis B vaccination. We selected six rare variant alleles and followed up their association with disease status by Sanger sequencing in a case-control study comprising 1,728 CHB patients and 1,636 healthy controls. The latter had either not been immunized with hepatitis B vaccine or had uncertain vaccination status. Our results showed that transmembrane protein 2 p.Ser1254Asn, interferon alpha 2 p.Ala120Thr, its regulator NLR family member X1 p.Arg707Cys, and complement component 2 p.Glu318Asp were associated with CHB, with P values of <1.0 × 10−7, 2.76 × 10−5, 5.08 × 10−5, 2.78 × 10−4 and odds ratios (ORs) of 2.45, 4.08, 2.34, and 1.97, respectively. The combined P value was <2.0 × 10−16. As there has been no indication of immunological functions for the associated gene, transmembrane protein 2, we further studied its expression by immunohistochemistry, real-time polymerase chain reaction, and western blotting. Our results showed that it was strongly expressed by healthy hepatocytes, but its expression was reduced in liver tissues with CHB, hepatitis B viral (HBV) genome-containing HepG2.2.15 cells, as compared with healthy liver tissues and non-HBV genome-containing HepG2 cells (P = 0.022 and 0.0036, respectively). Conclusion: We identified four missense mutations associated with CHB, our results providing evidence for rare inborn genetic defects that contribute to increased host susceptibility to CHB. (HEPATOLOGY 2012;56:1661–1670)